Biobanking and Immunologic Monitoring

生物样本库和免疫监测

• 批准号: 10493797
• 负责人: JEROME RITZ
• 金额: $ 28.26万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10493797
• 关键词: Adult; Allogenic; Antigen Targeting; Biological Assay; Bone Marrow; Boston; Bronchoalveolar Lavage; Cells; Characteristics; Chronic; Clinical; Clinical Trials; Collection; Correlative Study; Cryopreservation; Cytomegalovirus; Cytometry; DNA; Dana-Farber Cancer Institute; Data; Disease; Dose; Enrollment; Enzyme-Linked Immunosorbent Assay; Equipment and supply inventories; Flow Cytometry; Fluorochrome; Hematopoietic Stem Cell Transplantation; Hospitals; Human Herpesvirus 4; Immunity; Immunologic Monitoring; Individual; Informed Consent; Institutional Review Boards; Interleukin-2; Intervention; Kinetics; Laboratories; Lymphocyte; Measures; Metals; Monitor; Monoclonal Antibodies; Mononuclear; Outcome; Patient-Focused Outcomes; Patients; Pediatric Hospitals; Peripheral Blood Mononuclear Cell; Phenotype; Plasma; Play; Policies; Population; Principal Investigator; Process; Protocols documentation; RNA; Research Personnel; Resources; Role; Sampling; Serum; Stem cell transplant; T-Lymphocyte; Therapeutic Agents; Time; Tissue Banks; Transplantation; Woman; antibody conjugate; biobank; chronic graft versus host disease; computerized; cytokine; donor stem cell; enzyme linked immunospot assay; experimental study; immune function; immune reconstitution; immunological intervention; improved; novel therapeutics; patient privacy; pediatric patients; peripheral blood; prevent; programs; prospective; reconstitution; research study; sample collection; transplant database

Core 2 Project Summary/Abstract The purpose of this core is to provide a centralized laboratory resource for obtaining, cryopreserving and distributing patient samples and to monitor the kinetics of immune reconstitution following allogeneic hematopoietic stem cell transplantation (HCT) and following immune interventions to prevent or treat chronic GVHD. Prior to transplantation, peripheral blood mononuclear cells (PBMC), bone marrow and serum or plasma are obtained from all patients enrolled on clinical trials supported by this Program Project. PBMC, plasma and serum are also obtained from patients undergoing routine allogenic stem cell transplantation and normal stem cell donors for these individuals. Following HCT, peripheral blood, plasma and DNA samples are obtained at regular intervals. All of these samples are processed, cryopreserved, entered into a computerized inventory and made available to all of the investigators in this program. The HCT tissue bank inventory also has a very large number of serial samples from patients who have previously undergone allogeneic HCT at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Boston Children’s Hospital. Clinical outcome data on these patients is available in our HCT database. This inventory of annotated samples is also available to Program investigators. Finally, the tissue bank inventory includes serial samples obtained from previous clinical trials evaluating low dose IL-2 and other novel therapeutic agents in patients with chronic graft versus host disease (cGVHD). All banked samples have been collected from patients who have provided informed consent for sample collection for research studies. To monitor immune reconstitution after allogeneic HCT as well as interventions to prevent or treat GVHD, this core utilizes multi-parameter flow cytometry with a panel of fluorochrome- conjugated monoclonal antibodies or mass cytometry with panels of metal-conjugated antibodies. If needed, plasma concentrations of cytokines known to play important roles in immune reconstitution are measured by ELISA or panels of cytokines can be measured by Luminex. Reconstitution of T cell immunity to specific target antigens such as CMV and EBV is determined by ELISPOT and HLA-tetramers. Results of each of these assays are correlated with other parameters of immune function as well as with clinical outcomes.

核心2项目摘要/摘要 该核心的目的是为获得，冷冻水平和 分发患者样品并监测同种异体后的免疫重建的动力学 造血干细胞移植（HCT）和免疫干预后以预防或治疗慢性 GVHD。移植之前，外周血单核细胞（PBMC），骨髓和血清或血浆 从该计划项目支持的所有参加临床试验的患者中获得。 PBMC，等离子体和 还可以从接受常规可替代的干细胞移植和正常茎的患者获得血清 这些人的细胞供体。在HCT之后，获得外周血，血浆和DNA样品 定期间隔。所有这些样本均经过处理，冷冻保存，进入计算机化库存，并 该计划中的所有调查员都可以使用。 HCT组织库库存也很大 以前在Dana-Farber上接受过同种异体HCT的患者的连续样品数量 癌症研究所，杨百翰和妇女医院和波士顿儿童医院。这些有关这些的临床结果数据 患者在我们的HCT数据库中可用。该注释样本的库存也可以进行编程 调查人员。最后，组织库库存包括从以前的临床试验中获得的连续样品 评估慢性移植与宿主疾病患者的低剂量IL-2和其他新型治疗剂 （CGVHD）。所有存储样本均已从已提供样本的知情同意的患者那里收集 研究收集。在同种异体HCT和干预措施后监测免疫重建 为了防止或治疗GVHD，该核心使用一组荧光色体的多参数流式细胞仪 与金属偶联抗体面板的共轭单克隆抗体或质量细胞仪。如果需要， 已知在免疫重建中起重要作用的细胞因子的血浆浓度由 ELISA或细胞因子的面板可以通过Luminex测量。将T细胞免疫重建对特定靶标 CMV和EBV等抗原由ELISPOT和HLA四聚体确定。这些测定中的每一个的结果 与免疫功能的其他参数以及临床结果相关。